Literature DB >> 21543874

Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein.

Galina Polekhina1, David Benjamin Ascher, Shie Foong Kok, Mark Waltham.   

Abstract

Thioredoxin-interacting protein (TXNIP) is a negative regulator of thioredoxin and its roles in the pathologies of diabetes and cardiovascular diseases have marked it out as a potential drug target. Expression of TXNIP is robustly induced under various stress conditions such as high glucose, heat shock, UV, H(2)O(2) and mechanical stress amongst others. Elevated levels of TXNIP result in the sequestration and inactivation of thioredoxin, leading to cellular oxidative stress. For some time, this was the only known function of TXNIP; however, more recently the protein has been shown to play a role in regulation of glucose uptake and activation of the inflammasome. Based on the primary sequence, TXNIP is remotely related to β-arrestins, which include the visual arrestins. TXNIP has thus been classified as a member of the α-arrestin family, which to date includes five other members. None of the other α-arrestins are known to interact with thioredoxin, although curiously one has been implicated in glucose uptake. In order to gain insight into the structure-function relationships of the α-arrestin protein family, and particularly that of TXNIP, the N-terminal domain of TXNIP has been crystallized. The crystals belonged to a monoclinic space group and diffracted to 3 Å resolution using synchrotron radiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543874      PMCID: PMC3087653          DOI: 10.1107/S1744309111010347

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  27 in total

1.  Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis.

Authors:  Shawn K Milano; Helen C Pace; You-Me Kim; Charles Brenner; Jeffrey L Benovic
Journal:  Biochemistry       Date:  2002-03-12       Impact factor: 3.162

2.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines.

Authors:  Timothy M McPhillips; Scott E McPhillips; Hsiu-Ju Chiu; Aina E Cohen; Ashley M Deacon; Paul J Ellis; Elspeth Garman; Ana Gonzalez; Nicholas K Sauter; R Paul Phizackerley; S Michael Soltis; Peter Kuhn
Journal:  J Synchrotron Radiat       Date:  2002-11-01       Impact factor: 2.616

3.  A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site.

Authors:  Lucy Stols; Minyi Gu; Lynda Dieckman; Rosemarie Raffen; Frank R Collart; Mark I Donnelly
Journal:  Protein Expr Purif       Date:  2002-06       Impact factor: 1.650

4.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

5.  Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function.

Authors:  E Junn; S H Han; J Y Im; Y Yang; E W Cho; H D Um; D K Kim; K W Lee; P L Han; S G Rhee; I Choi
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

6.  Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.

Authors:  A Weichsel; J R Gasdaska; G Powis; W R Montfort
Journal:  Structure       Date:  1996-06-15       Impact factor: 5.006

7.  Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein.

Authors:  P Christian Schulze; Jun Yoshioka; Tomosaburo Takahashi; Zhiheng He; George L King; Richard T Lee
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

8.  Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells.

Authors:  Tsutomu Kobayashi; Sayuri Uehara; Takanori Ikeda; Hiraku Itadani; Hidehito Kotani
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

9.  Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals.

Authors:  To Yuen Hui; Sonal S Sheth; J Matthew Diffley; Douglas W Potter; Aldons J Lusis; Alan D Attie; Roger A Davis
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

10.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  5 in total

Review 1.  Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.

Authors:  Samuel Lee; Soo Min Kim; Richard T Lee
Journal:  Antioxid Redox Signal       Date:  2012-06-26       Impact factor: 8.401

Review 2.  Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit.

Authors:  Islam N Mohamed; Tauheed Ishrat; Susan C Fagan; Azza B El-Remessy
Journal:  Antioxid Redox Signal       Date:  2014-11-11       Impact factor: 8.401

Review 3.  Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology.

Authors:  S Schlee; L C Bollheimer; T Bertsch; C C Sieber; P Härle
Journal:  Z Gerontol Geriatr       Date:  2017-02-23       Impact factor: 1.281

Review 4.  Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell.

Authors:  Anath Shalev
Journal:  Mol Endocrinol       Date:  2014-06-09

5.  Thioredoxin-interacting protein regulates protein disulfide isomerases and endoplasmic reticulum stress.

Authors:  Samuel Lee; Soo Min Kim; James Dotimas; Letitia Li; Edward P Feener; Stephan Baldus; Ronald B Myers; William A Chutkow; Parth Patwari; Jun Yoshioka; Richard T Lee
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.